Exercise That Feels as Good as Possible: Acceptability of an Affect-Based Exercise Prescription Among Stage 0-III Breast Cancer Survivors.

IF 3.5 2区医学 Q2 ONCOLOGY

Psycho‐Oncology Pub Date : 2025-08-01 DOI:10.1002/pon.70225

Courtney J Stevens, Carly A Bobak, Kali J Morrissette, Ryan C Thompson, Kathleen Doyle Lyons, Grace M Wallace, Amanda J Emerson, David E Conroy, David M Williams, Mary D Chamberlin, Martha L Bruce

{"title":"Exercise That Feels as Good as Possible: Acceptability of an Affect-Based Exercise Prescription Among Stage 0-III Breast Cancer Survivors.","authors":"Courtney J Stevens, Carly A Bobak, Kali J Morrissette, Ryan C Thompson, Kathleen Doyle Lyons, Grace M Wallace, Amanda J Emerson, David E Conroy, David M Williams, Mary D Chamberlin, Martha L Bruce","doi":"10.1002/pon.70225","DOIUrl":null,"url":null,"abstract":"Background: Leaders in the field have called for exercise counseling to become standard of care by 2029. An Affect-based exercise prescription (Affect-Rx) may be a viable strategy for supporting this effort.Aims: Guided by the ORBIT Model for developing behavioral treatments, this Phase 1b study evaluated breast cancer survivors' perceived acceptability of Affect-Rx. Additionally, the feasibility of trial methods and opportunities for protocol refinements were assessed.Method: Participants were 36 stage 0-III breast cancer survivors within 5 years of completing primary cancer treatment. Demographics were collected at baseline and via medical record review. Affect-Rx was delivered in conjunction with a low-touch, physical activity promotion intervention over videoconference call. At end-of-study, participants rated Affect-Rx using the Treatment Acceptability and Preferences (TAP) Measure. Participants responded to the Stanford L-Cat at baseline and end-of-study. ActiGraph wGT3X-BT accelerometers measured moderate-vigorous physical activity (MVPA) over 10-day periods at baseline and follow-up.Results: Affect-Rx was rated acceptable (TAP overall M = 3.30, SD = 0.53). Study retention and accelerometer measurement completion was ≥ 80% across time. L-Cat scores were discordant from accelerometer-measured MVPA at baseline.Conclusions: Affect-Rx warrants further testing. The trial methods were feasible; however, physical inactivity verification procedures along with targeted recruitment efforts are needed to support future work. The field needs intervention strategies that can be deployed with limited resources and at low cost to offer survivors exercise counseling support in line with the new National Standards for Cancer Survivorship Care, the affect-based exercise prescription is designed to serve this mission.Trial registration: The study protocol was registered with ClinicalTrials.gov prior to the initiation of participant recruitment NCT04903249.","PeriodicalId":20779,"journal":{"name":"Psycho‐Oncology","volume":"34 8","pages":"e70225"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412301/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psycho‐Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pon.70225","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Leaders in the field have called for exercise counseling to become standard of care by 2029. An Affect-based exercise prescription (Affect-Rx) may be a viable strategy for supporting this effort.

Aims: Guided by the ORBIT Model for developing behavioral treatments, this Phase 1b study evaluated breast cancer survivors' perceived acceptability of Affect-Rx. Additionally, the feasibility of trial methods and opportunities for protocol refinements were assessed.

Method: Participants were 36 stage 0-III breast cancer survivors within 5 years of completing primary cancer treatment. Demographics were collected at baseline and via medical record review. Affect-Rx was delivered in conjunction with a low-touch, physical activity promotion intervention over videoconference call. At end-of-study, participants rated Affect-Rx using the Treatment Acceptability and Preferences (TAP) Measure. Participants responded to the Stanford L-Cat at baseline and end-of-study. ActiGraph wGT3X-BT accelerometers measured moderate-vigorous physical activity (MVPA) over 10-day periods at baseline and follow-up.

Results: Affect-Rx was rated acceptable (TAP overall M = 3.30, SD = 0.53). Study retention and accelerometer measurement completion was ≥ 80% across time. L-Cat scores were discordant from accelerometer-measured MVPA at baseline.

Conclusions: Affect-Rx warrants further testing. The trial methods were feasible; however, physical inactivity verification procedures along with targeted recruitment efforts are needed to support future work. The field needs intervention strategies that can be deployed with limited resources and at low cost to offer survivors exercise counseling support in line with the new National Standards for Cancer Survivorship Care, the affect-based exercise prescription is designed to serve this mission.

Trial registration: The study protocol was registered with ClinicalTrials.gov prior to the initiation of participant recruitment NCT04903249.

查看原文本刊更多论文

感觉尽可能好的运动：在0- 3期乳腺癌幸存者中基于情感的运动处方的可接受性

背景：该领域的领导者呼吁到2029年运动咨询成为标准护理。基于情感的运动处方（Affect-Rx）可能是支持这一努力的可行策略。目的：在ORBIT模型的指导下开发行为治疗，本1b期研究评估乳腺癌幸存者对Affect-Rx的可接受性。此外，还评估了试验方法的可行性和方案改进的机会。方法：参与者为36名完成原发性癌症治疗5年内的0-III期乳腺癌幸存者。在基线和通过医疗记录审查收集人口统计数据。Affect-Rx与低触碰、通过视频电话会议进行的体育活动促进干预相结合。在研究结束时，参与者使用治疗可接受性和偏好（TAP）测量对影响- rx进行评分。参与者在基线和研究结束时对斯坦福L-Cat有反应。ActiGraph wgt3g - bt加速度计在基线和随访期间测量了10天的中度剧烈身体活动（MVPA）。结果：impact - rx被评为可接受（TAP总体M = 3.30, SD = 0.53）。研究保留度和加速度计测量完成度≥80%。L-Cat评分与基线时加速度计测量的MVPA不一致。结论：影响- rx值得进一步测试。试验方法可行；但是，为了支持今后的工作，需要有针对性的征聘工作以及缺乏运动的核查程序。该领域需要能够以有限的资源和低成本部署的干预策略，为幸存者提供符合新的国家癌症幸存者护理标准的运动咨询支持，基于影响的运动处方旨在服务于这一任务。试验注册：研究方案在受试者招募开始前已在ClinicalTrials.gov注册，编号NCT04903249。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Psycho‐Oncology 医学-心理学

CiteScore

6.30

自引率

8.30%

发文量

220

审稿时长

3-8 weeks

期刊介绍： Psycho-Oncology is concerned with the psychological, social, behavioral, and ethical aspects of cancer. This subspeciality addresses the two major psychological dimensions of cancer: the psychological responses of patients to cancer at all stages of the disease, and that of their families and caretakers; and the psychological, behavioral and social factors that may influence the disease process. Psycho-oncology is an area of multi-disciplinary interest and has boundaries with the major specialities in oncology: the clinical disciplines (surgery, medicine, pediatrics, radiotherapy), epidemiology, immunology, endocrinology, biology, pathology, bioethics, palliative care, rehabilitation medicine, clinical trials research and decision making, as well as psychiatry and psychology. This international journal is published twelve times a year and will consider contributions to research of clinical and theoretical interest. Topics covered are wide-ranging and relate to the psychosocial aspects of cancer and AIDS-related tumors, including: epidemiology, quality of life, palliative and supportive care, psychiatry, psychology, sociology, social work, nursing and educational issues. Special reviews are offered from time to time. There is a section reviewing recently published books. A society news section is available for the dissemination of information relating to meetings, conferences and other society-related topics. Summary proceedings of important national and international symposia falling within the aims of the journal are presented.